Hydrocortisone in the management of dengue shock syndrome.
A total of 98 patients with dengue shock syndrome admitted into Children's Hospital from February 1973 to February 1974 were randomly selected into 2 groups. A double blind controlled trial of the efficacy of pharmacologic doses of hydrocortisone hemisuccinate was carried out. The 2 groups were confirmed to be completely matched by age, sex and severity of the disease. Nine deaths occurred out of 48 cases in the steroid group (Case Fatality Rate 18.75%) and 22 deaths out of 50 cases in the non-steroid group (Case Fatality Rate 44%), the difference being statistically significant. No significant difference was detected in fluid requirements and other morbidity pattern.
D001794:Blood Pressure / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003715:Dengue / Q000188:drug therapy* / Q000401:mortality; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use*; D007223:Infant; D002052:Myanmar; D012771:Shock, Hemorrhagic / Q000188:drug therapy* / Q000401:mortality
D006854:Hydrocortisone